PDAC
Clinical trials for PDAC explained in plain language.
Never miss a new study
Get alerted when new PDAC trials appear
Sign up with your email to follow new studies for PDAC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, alone or with standard chemotherapy, in people with metastatic pancreatic cancer that has spread. About 900 adults with a RAS gene mutation will be randomly assigned to one of three treatment groups. The goal is to see if the new d…
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
New pill aims to keep pancreatic cancer at bay after surgery
Disease control Recruiting nowThis study tests a new drug called daraxonrasib to see if it can delay or prevent pancreatic cancer from returning after surgery and chemotherapy. About 500 adults who have had their pancreatic cancer removed will be randomly assigned to receive the drug or just be watched. The g…
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 11:38 UTC
-
New drug duo targets tough KRAS mutation in advanced cancers
Disease control Recruiting nowThis study tests two drugs, IN10018 and RNK08954, together in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or metastati…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 11:34 UTC
-
New hope for hard-to-treat cancers: drug combo targets genetic weakness
Disease control Recruiting nowThis study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 11:33 UTC
-
New drug cocktails take on Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies for people with advanced colorectal or pancreatic cancer. The goal is to see if these combinations are safe and can shrink tumors. About 1,130…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 11:31 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…
Matched conditions: PDAC
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for hard-to-treat cancers: targeted combo therapy enters human trials
Disease control Recruiting nowThis study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New registry aims to catch deadly pancreatic cancer before it spreads
Knowledge-focused Recruiting nowThis study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use these samples to develop and validate tests for early detection, including AI-assisted analysis. Participants must be 18 o…
Matched conditions: PDAC
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 17, 2026 11:35 UTC